Works by Hirata, Jamie

Results: 9

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients.
Published in:
Journal of Cancer Research & Therapeutics, 2024, v. 20, n. 7, p. 2133, doi. 10.4103/jcrt.jcrt_269_24
By:
- Song, Yuqin;
- Zhang, Qingyuan;
- Cai, Qingqing;
- Song, Yongping;
- Zhang, Liling;
- He, Pengcheng;
- Wang, Li;
- Hirata, Jamie;
- Musick, Lisa;
- Deng, Rong;
- Liu, Wenxin;
- Wang, Xin;
- Zhu, Jun
Publication type:
Article
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX.
Published in:
CTS: Clinical & Translational Science, 2023, v. 16, n. 12, p. 2744, doi. 10.1111/cts.13669
By:
- Liao, Michael Z.;
- Deng, Rong;
- Gibiansky, Leonid;
- Lu, Tong;
- Agarwal, Priya;
- Dere, Randall;
- Lee, Calvin;
- Hirata, Jamie;
- Herbaux, Charles;
- Salles, Gilles;
- Li, Chunze;
- Miles, Dale
Publication type:
Article
Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States.
Published in:
Cancer (0008543X), 2012, v. 118, n. 19, p. 4842, doi. 10.1002/cncr.27513
By:
- Nabhan, Chadi;
- Byrtek, Michelle;
- Taylor, Michael D.;
- Friedberg, Jonathan W.;
- Cerhan, James R.;
- Hainsworth, John D.;
- Miller, Thomas P.;
- Hirata, Jamie;
- Link, Brian K.;
- Flowers, Christopher R.
Publication type:
Article
Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
Published in:
CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 6, p. 1055, doi. 10.1002/psp4.13141
By:
- Deng, Rong;
- Gibiansky, Leonid;
- Lu, Tong;
- Flowers, Christopher R.;
- Sehn, Laurie H.;
- Liu, Qi;
- Agarwal, Priya;
- Liao, Michael Z.;
- Dere, Randall;
- Lee, Calvin;
- Man, Gabriel;
- Hirata, Jamie;
- Li, Chunze;
- Miles, Dale
Publication type:
Article
Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma.
Published in:
CPT: Pharmacometrics & Systems Pharmacology, 2020, v. 9, n. 1, p. 48, doi. 10.1002/psp4.12482
By:
- Lu, Dan;
- Lu, Tong;
- Gibiansky, Leonid;
- Li, Xiaobin;
- Li, Chunze;
- Agarwal, Priya;
- Shemesh, Colby S.;
- Shi, Rong;
- Dere, Randall C.;
- Hirata, Jamie;
- Miles, Dale;
- Chanu, Pascal;
- Girish, Sandhya;
- Jin, Jin Yan
Publication type:
Article
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
Published in:
Leukemia & Lymphoma, 2020, v. 61, n. 12, p. 2905, doi. 10.1080/10428194.2020.1795154
By:
- Lu, Tong;
- Gibiansky, Leonid;
- Li, Xiaobin;
- Li, Chunze;
- Shi, Rong;
- Agarwal, Priya;
- Hirata, Jamie;
- Miles, Dale;
- Chanu, Pascal;
- Girish, Sandhya;
- Jin, Jin Yan;
- Lu, Dan
Publication type:
Article
Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma.
Published in:
American Journal of Hematology, 2024, v. 99, n. 7, p. 1281, doi. 10.1002/ajh.27341
By:
- Yuen, Sam;
- Phillips, Tycel J.;
- Bannerji, Rajat;
- Marlton, Paula;
- Gritti, Giuseppe;
- Seymour, John F.;
- Johnston, Anna;
- Arthur, Christopher;
- Dodero, Anna;
- Sharma, Sunil;
- Hirata, Jamie;
- Musick, Lisa;
- Flowers, Christopher R.
Publication type:
Article
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study.
Published in:
American Journal of Hematology, 2022, v. 97, n. 1, p. E24, doi. 10.1002/ajh.26400
By:
- Phillips, Tycel;
- Brunvand, Mark;
- Chen, Andy I.;
- Essell, James;
- Chiappella, Annalisa;
- Diefenbach, Catherine;
- Cheng, Ji;
- Ramies, David;
- Hirata, Jamie;
- Morschhauser, Franck;
- Flinn, Ian W.
Publication type:
Article
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Published in:
Pharmaceutical Research, 2020, v. 37, n. 12, p. 1, doi. 10.1007/s11095-020-02933-6
By:
- Lu, Dan;
- Lu, Tong;
- Shi, Rong;
- Gibiansky, Leonid;
- Agarwal, Priya;
- Shemesh, Colby S.;
- Dere, Randall C.;
- Ogbu, Uzor;
- Hirata, Jamie;
- Chanu, Pascal;
- Girish, Sandhya;
- Jin, Jin Yan;
- Li, Chunze;
- Miles, Dale
Publication type:
Article